Published in J Med Genet on January 01, 1996
Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. Am J Hum Genet (2001) 2.78
Ras in cancer and developmental diseases. Genes Cancer (2011) 2.68
A clinical study of type 1 neurofibromatosis in north west England. J Med Genet (1999) 1.62
Confirmation of a double-hit model for the NF1 gene in benign neurofibromas. Am J Hum Genet (1997) 1.55
Disorders of dysregulated signal traffic through the RAS-MAPK pathway: phenotypic spectrum and molecular mechanisms. Ann N Y Acad Sci (2010) 1.54
A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor. Nat Rev Cancer (2015) 1.40
Structural analysis of the GAP-related domain from neurofibromin and its implications. EMBO J (1998) 1.30
Mortality associated with neurofibromatosis 1: a cohort study of 1895 patients in 1980-2006 in France. Orphanet J Rare Dis (2011) 1.16
Molecular and cellular mechanisms of learning disabilities: a focus on NF1. Annu Rev Neurosci (2010) 1.04
Recurrent chromosomal imbalances and structurally abnormal breakpoints within complex karyotypes of malignant peripheral nerve sheath tumour and malignant triton tumour: a cytogenetic and molecular cytogenetic study. J Clin Pathol (2004) 1.00
Estimate of de novo mutation frequency in probands with PTEN hamartoma tumor syndrome. Genet Med (2012) 0.99
Hypoxia-inducible factor signaling in pheochromocytoma: turning the rudder in the right direction. J Natl Cancer Inst (2013) 0.98
Constitutional and mosaic large NF1 gene deletions in neurofibromatosis type 1. J Med Genet (1998) 0.97
Genetics of the hamartomatous polyposis syndromes: a molecular review. Int J Colorectal Dis (2009) 0.95
Neurofibromatosis type 1 (NF1): a protein truncation assay yielding identification of mutations in 73% of patients. J Med Genet (1998) 0.95
Growth in North American white children with neurofibromatosis 1 (NF1). J Med Genet (2000) 0.94
Identification of growth hormone receptor in plexiform neurofibromas of patients with neurofibromatosis type 1. Clinics (Sao Paulo) (2008) 0.93
Gastric carcinoid: germline and somatic mutation of the neurofibromatosis type 1 gene. Fam Cancer (2007) 0.90
Paragangliomas/Pheochromocytomas: clinically oriented genetic testing. Int J Endocrinol (2014) 0.89
A case of neurofibromatosis and multiple sclerosis. Neurol Sci (2010) 0.89
Disturbed osteoblastic differentiation of fibrous hamartoma cell from congenital pseudarthrosis of the tibia associated with neurofibromatosis type I. Clin Orthop Surg (2011) 0.87
Neurofibromatosis presenting with a cherubism phenotype. Eur J Pediatr (2006) 0.86
Hereditary spinal neurofibromatosis: a rare form of NF1? J Med Genet (1997) 0.83
Spinal reconstruction with pedicle screw-based instrumentation and rhBMP-2 in patients with neurofibromatosis and severe dural ectasia and spinal deformity: report of two cases and a review of the literature. J Bone Joint Surg Am (2011) 0.82
Unusual clustering of brain tumours in a family with NF1 and variable expression of cutaneous features. J Med Genet (1999) 0.81
Rare variants in hypermutable genes underlie common morphology and growth traits in wild Saccharomyces paradoxus. Genetics (2013) 0.79
NFFinder: an online bioinformatics tool for searching similar transcriptomics experiments in the context of drug repositioning. Nucleic Acids Res (2015) 0.79
Globus pallidus high-signal lesions: A predominant MRI finding in children with neurofibromatosis type 1. Ann Indian Acad Neurol (2013) 0.78
Proton MR spectroscopic imaging of basal ganglia and thalamus in neurofibromatosis type 1: correlation with T2 hyperintensities. Neuroradiology (2010) 0.77
Focal segmental glomerulosclerosis in association with neurofibromatosis type 1: a case report and proposed molecular pathways. Clin Kidney J (2013) 0.76
The NF1 gene in tumor syndromes and melanoma. Lab Invest (2017) 0.75
Clinical Images: Imaging Manifestations of Orbital Neurofibromatosis Type 1. Ochsner J (2016) 0.75
Von recklinghausens disease: a series of four cases with variable expression. J Maxillofac Oral Surg (2013) 0.75
A brother and sister with breast cancer, BRCA2 mutations and bilateral supernumerary nipples. Ann Transl Med (2017) 0.75
Peripheral retinal ischemia in a young Indian woman with neurofibromatosis type 1. Saudi J Ophthalmol (2015) 0.75
Isolated plexiform neurofibroma over left palm: a case report and review of literature. Indian J Dermatol (2013) 0.75
Neurofibromatosis type 1 and pregnancy: The transformation of a nodular to cystic neurofibroma in the cervical region. Surg Neurol Int (2015) 0.75
Giant malignant peripheral nerve sheath tumor with cauda equina syndrome and subarachnoid hemorrhage: Complications in a case of type 1 neurofibromatosis. J Nat Sci Biol Med (2015) 0.75
Genetics of pancreatic neuroendocrine tumors: implications for the clinic. Expert Rev Gastroenterol Hepatol (2015) 0.75
Familial Lymphoproliferative Malignancies and Tandem Duplication of NF1 Gene. Case Rep Oncol Med (2014) 0.75
Does pamidronate enhance the osteogenesis in mesenchymal stem cells derived from fibrous hamartoma in congenital pseudarthrosis of the tibia? Bone Rep (2016) 0.75
Rare Presentation of Neurofibromatosis and Turner Syndrome in a Pediatric Patient. Pediatr Rep (2017) 0.75
Familial Myelodysplastic/Acute Leukemia Syndromes-Myeloid Neoplasms with Germline Predisposition. Front Oncol (2017) 0.75
A genetic model for colorectal tumorigenesis. Cell (1990) 44.37
Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A (1971) 31.05
ras genes. Annu Rev Biochem (1987) 22.59
ras oncogenes in human cancer: a review. Cancer Res (1989) 22.03
Molecular basis of base substitution hotspots in Escherichia coli. Nature (1978) 13.79
The GTPase superfamily: a conserved switch for diverse cell functions. Nature (1990) 11.71
Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science (1990) 8.91
Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol (1988) 8.61
The p21 src genes of Harvey and Kirsten sarcoma viruses originate from divergent members of a family of normal vertebrate genes. Nature (1981) 8.44
A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell (1990) 8.10
Mutation rates differ among regions of the mammalian genome. Nature (1989) 7.63
Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell (1990) 6.94
Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature (1993) 6.67
Phosphorylation of GAP and GAP-associated proteins by transforming and mitogenic tyrosine kinases. Nature (1990) 5.57
The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell (1990) 5.24
Nonsense mutations in the dihydrofolate reductase gene affect RNA processing. Mol Cell Biol (1989) 5.19
Gene for von Recklinghausen neurofibromatosis is in the pericentromeric region of chromosome 17. Science (1987) 5.11
The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell (1990) 4.84
Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain (1988) 4.69
Guanosine triphosphatase activating protein (GAP) interacts with the p21 ras effector binding domain. Science (1988) 4.58
A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity. J Med Genet (1989) 4.42
Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature (1992) 4.42
PDGF induction of tyrosine phosphorylation of GTPase activating protein. Nature (1989) 4.36
The cytoplasmic protein GAP is implicated as the target for regulation by the ras gene product. Nature (1988) 4.33
The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell (1990) 4.12
Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat Genet (1994) 3.97
Noonan syndrome. J Med Genet (1987) 3.70
Genetic linkage of von Recklinghausen neurofibromatosis to the nerve growth factor receptor gene. Cell (1987) 3.60
The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae. Cell (1990) 3.56
Gene deletions causing human genetic disease: mechanisms of mutagenesis and the role of the local DNA sequence environment. Hum Genet (1991) 3.48
Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev (1994) 3.40
Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell (1992) 3.30
A de novo Alu insertion results in neurofibromatosis type 1. Nature (1991) 3.29
Precise localization of NF1 to 17q11.2 by balanced translocation. Am J Hum Genet (1989) 3.27
Consequences of frameshift mutations at the immunoglobulin heavy chain locus of the mouse. EMBO J (1985) 3.25
Somatic mutations in the neurofibromatosis 1 gene in human tumors. Cell (1992) 3.20
Regional mapping panel for human chromosome 17: application to neurofibromatosis type 1. Genomics (1987) 3.12
S. cerevisiae genes IRA1 and IRA2 encode proteins that may be functionally equivalent to mammalian ras GTPase activating protein. Cell (1990) 3.09
Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med (1994) 2.81
An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes. Am J Hum Genet (1993) 2.79
ras GTPase activating protein: signal transmitter and signal terminator. Cell (1989) 2.78
The mutational spectrum of single base-pair substitutions causing human genetic disease: patterns and predictions. Hum Genet (1990) 2.59
Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc Natl Acad Sci U S A (1990) 2.52
Genetic analysis of mammalian GAP expressed in yeast. Cell (1989) 2.44
Neurofibromatosis: clinical heterogeneity. Curr Probl Cancer (1982) 2.43
IRA2, a second gene of Saccharomyces cerevisiae that encodes a protein with a domain homologous to mammalian ras GTPase-activating protein. Mol Cell Biol (1990) 2.40
Cellular ras activity and phospholipid metabolism. Cell (1988) 2.35
Ras C-terminal processing enzymes--new drug targets? Cell (1991) 2.31
Sequence homology shared by neurofibromatosis type-1 gene and IRA-1 and IRA-2 negative regulators of the RAS cyclic AMP pathway. Nature (1990) 2.28
Beta-globin nonsense mutation: deficient accumulation of mRNA occurs despite normal cytoplasmic stability. Proc Natl Acad Sci U S A (1992) 2.13
Current methods of mutation detection. Mutat Res (1993) 2.12
Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis. Nat Genet (1993) 2.10
A transgenic mouse model for human neurofibromatosis. Science (1987) 2.05
Multipoint linkage analysis in neurofibromatosis type I: an international collaboration. Am J Hum Genet (1989) 2.04
cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of the NF1 gene product. Genomics (1991) 2.03
Microtubule dynamics: mechanism, regulation, and function. Annu Rev Cell Biol (1991) 2.02
A nonsense mutation causing decreased levels of insulin receptor mRNA: detection by a simplified technique for direct sequencing of genomic DNA amplified by the polymerase chain reaction. Proc Natl Acad Sci U S A (1990) 1.90
A genetic study of von Recklinghausen neurofibromatosis in south east Wales. II. Guidelines for genetic counselling. J Med Genet (1989) 1.87
The effect of GTPase activating protein upon ras is inhibited by mitogenically responsive lipids. Science (1989) 1.86
p53: the ultimate tumor suppressor gene? FASEB J (1992) 1.85
Linkage disequilibrium in the neurofibromatosis 1 (NF1) region: implications for gene mapping. Am J Hum Genet (1993) 1.83
Pulmonary stenosis, café-au-lait spots, and dull intelligence. Arch Dis Child (1967) 1.82
Doyne Lecture. Rhodopsin and autosomal dominant retinitis pigmentosa. Eye (Lond) (1992) 1.80
Tightly linked markers for the neurofibromatosis type 1 gene. Genomics (1987) 1.68
Novel metabolism of several beta zero-thalassemic beta-globin mRNAs in the erythroid tissues of transgenic mice. EMBO J (1989) 1.68
Tandem duplication within a type II collagen gene (COL2A1) exon in an individual with spondyloepiphyseal dysplasia. Proc Natl Acad Sci U S A (1990) 1.66
The human homolog of murine Evi-2 lies between two von Recklinghausen neurofibromatosis translocations. Genomics (1990) 1.66
Familial neurofibromatosis type 1: clinical experience with DNA testing. J Pediatr (1992) 1.65
Paternal origin of new mutations in von Recklinghausen neurofibromatosis. Nature (1990) 1.64
ras and GAP--who's controlling whom? Cell (1990) 1.63
Severe deficiency of cystic fibrosis transmembrane conductance regulator messenger RNA carrying nonsense mutations R553X and W1316X in respiratory epithelial cells of patients with cystic fibrosis. J Clin Invest (1991) 1.56
Deletions spanning the neurofibromatosis 1 gene: identification and phenotype of five patients. Am J Hum Genet (1994) 1.56
Neurofibromatosis type 1 gene mutations in neuroblastoma. Nat Genet (1993) 1.48
Mutations in the neurofibromatosis 1 gene in sporadic malignant melanoma cell lines. Nat Genet (1993) 1.45
Mechanisms of insertional mutagenesis in human genes causing genetic disease. Hum Genet (1991) 1.44
Diagnosis of neurofibromatosis I by using tightly linked, flanking DNA markers. Am J Hum Genet (1990) 1.44
A conserved alternative splice in the von Recklinghausen neurofibromatosis (NF1) gene produces two neurofibromin isoforms, both of which have GTPase-activating protein activity. Mol Cell Biol (1993) 1.43
Neurofibromatosis and childhood leukemia. J Pediatr (1978) 1.41
Identification and characterization of transcripts from the neurofibromatosis 1 region: the sequence and genomic structure of EVI2 and mapping of other transcripts. Genomics (1990) 1.40
The protein product of the neurofibromatosis type 1 gene is expressed at highest abundance in neurons, Schwann cells, and oligodendrocytes. Neuron (1992) 1.39
The genetic aspects of neurofibromatosis. Ann N Y Acad Sci (1986) 1.38
Linkage of NF1 to 12 chromosome 17 markers: a summary of eight concurrent reports. Genomics (1987) 1.37
The neurofibromatosis type 1 gene and its protein product, neurofibromin. Neuron (1993) 1.36
New amber mutation in a beta-thalassemic gene with nonmeasurable levels of mutant messenger RNA in vivo. J Clin Invest (1988) 1.36
Animal models of human genetic diseases. Trends Genet (1993) 1.32
Signal transduction through small GTPases--a tale of two GAPs. Cell (1992) 1.31
Distribution of 13 truncating mutations in the neurofibromatosis 1 gene. Hum Mol Genet (1995) 1.30
Loss of NF1 alleles in phaeochromocytomas from patients with type I neurofibromatosis. Genes Chromosomes Cancer (1992) 1.29
Evi-2, a common integration site involved in murine myeloid leukemogenesis. Mol Cell Biol (1990) 1.29
A molecular survey of hypoxanthine-guanine phosphoribosyltransferase deficiency in man. J Clin Invest (1986) 1.28
Physical mapping of a translocation breakpoint in neurofibromatosis. Science (1989) 1.27
Role for the stem cell factor/KIT complex in Schwann cell neoplasia and mast cell proliferation associated with neurofibromatosis. J Neurosci Res (1994) 1.20
sar1, a gene from Schizosaccharomyces pombe encoding a protein that regulates ras1. Cell Regul (1991) 1.20
The oligodendrocyte-myelin glycoprotein belongs to a distinct family of proteins and contains the HNK-1 carbohydrate. J Cell Biol (1990) 1.19
Schwannomatosis. An unusual variant of neurofibromatosis or a distinct clinical entity? Arch Dermatol (1989) 1.16
Differential expression of two types of the neurofibromatosis type 1 (NF1) gene transcripts related to neuronal differentiation. Oncogene (1991) 1.15
Neurofibromin can inhibit Ras-dependent growth by a mechanism independent of its GTPase-accelerating function. Mol Cell Biol (1994) 1.14
Analysis of the neurofibromatosis type 1 (NF1) GAP-related domain by site-directed mutagenesis. Oncogene (1993) 1.14
Possible involvement of c-kit receptor and its ligand in increase of mast cells in neurofibroma tissues. Arch Pathol Lab Med (1993) 1.11
Characterization of full-length neurofibromin: tubulin inhibits Ras GAP activity. EMBO J (1993) 1.11
Linkage relationship of a cloned DNA sequence on the short arm of the X chromosome to Duchenne muscular dystrophy. Nature (1982) 11.57
Linkage analysis of two cloned DNA sequences flanking the Duchenne muscular dystrophy locus on the short arm of the human X chromosome. Nucleic Acids Res (1983) 8.92
Expansion of an unstable DNA region and phenotypic variation in myotonic dystrophy. Nature (1992) 8.85
Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat Genet (1993) 5.70
Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain (1988) 4.69
A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity. J Med Genet (1989) 4.42
Clinical aspects of X-linked hypohidrotic ectodermal dysplasia. Arch Dis Child (1987) 2.95
Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats. Am J Hum Genet (1996) 2.88
Frame-shift deletions in patients with Duchenne and Becker muscular dystrophy. Science (1988) 2.82
The prevention of Huntington's chorea. The Milroy lecture 1985. J R Coll Physicians Lond (1986) 2.74
Genetic risks for children of women with myotonic dystrophy. Am J Hum Genet (1991) 2.65
The use of linked DNA polymorphisms for genotype prediction in families with Duchenne muscular dystrophy. J Med Genet (1983) 2.45
Size of the unstable CTG repeat sequence in relation to phenotype and parental transmission in myotonic dystrophy. Am J Hum Genet (1993) 2.42
Estimation of the mutation frequencies in Charcot-Marie-Tooth disease type 1 and hereditary neuropathy with liability to pressure palsies: a European collaborative study. Eur J Hum Genet (1996) 2.40
Early-onset dystrophia myotonica. Evidence supporting a maternal environmental factor. Lancet (1972) 2.40
Unstable DNA sequence in myotonic dystrophy. Lancet (1992) 2.36
Huntington's Chorea in South Wales. A genetic and epidemiological study. Clin Genet (1981) 2.31
Blind analysis of denaturing high-performance liquid chromatography as a tool for mutation detection. Genomics (1998) 2.19
Studies of a DNA marker (G8) genetically linked to Huntington disease in British families. Hum Genet (1986) 2.18
Genetic linkage between Becker muscular dystrophy and a polymorphic DNA sequence on the short arm of the X chromosome. J Med Genet (1983) 2.16
Molecular analysis and clinical correlations of the Huntington's disease mutation. Lancet (1993) 2.15
Exclusion testing for Huntington's disease in pregnancy with a closely linked DNA marker. Lancet (1987) 2.09
Adoption and genetic prediction for Huntington's disease. Lancet (1988) 2.09
Effective strategy for prenatal prediction of Duchenne and Becker muscular dystrophy. Lancet (1987) 2.08
Polycystic kidney disease re-evaluated: a population-based study. Q J Med (1991) 2.05
Linkage disequilibrium in Huntington's disease: an improved localisation for the gene. J Med Genet (1989) 2.05
Congenital myotonic dystrophy in Britain. I. Clinical aspects. Arch Dis Child (1975) 2.04
Correlation between fragment size at D4F104S1 and age at onset or at wheelchair use, with a possible generational effect, accounts for much phenotypic variation in 4q35-facioscapulohumeral muscular dystrophy (FSHD) Hum Mol Genet (1995) 2.02
Problems in genetic prediction for Huntington's disease. Lancet (1989) 2.00
Cardiac disease in myotonic dystrophy. Cardiovasc Res (1997) 1.98
George Otto Gey. (1899-1970). The HeLa cell and a reappraisal of its origin. Obstet Gynecol (1971) 1.93
A new DNA marker tightly linked to the fragile X locus (FRAXA). Science (1989) 1.88
A genetic study of von Recklinghausen neurofibromatosis in south east Wales. II. Guidelines for genetic counselling. J Med Genet (1989) 1.87
Huntington's chorea. The basis for long-term prevention. Lancet (1979) 1.87
Genetic linkage confirmed between the locus for myotonic dystrophy and the ABH-secretion and Lutheran blood group loci. Am J Hum Genet (1972) 1.82
Factors influencing age at onset and duration of survival in Huntington's chorea. Ann Hum Genet (1981) 1.79
Screening for Duchenne muscular dystrophy. Arch Dis Child (1989) 1.78
Localisation of the Becker muscular dystrophy gene on the short arm of the X chromosome by linkage to cloned DNA sequences. Hum Genet (1984) 1.74
Attitudes of mothers to neonatal screening for Duchenne muscular dystrophy. BMJ (1990) 1.72
Congenital myotonic dystrophy in Britain. II. Genetic basis. Arch Dis Child (1975) 1.71
Huntington disease: no evidence for locus heterogeneity. Genomics (1989) 1.70
Attitudes of subjects at risk and their relatives towards genetic counselling in Huntington's chorea. J Med Genet (1983) 1.67
A clinical and genetic study of Hunter's syndrome. 2. Differences between the mild and severe forms. J Med Genet (1982) 1.66
Decline in the predicted incidence of Huntington's chorea associated with systematic genetic counselling and family support. Lancet (1981) 1.64
Detection of linkage disequilibrium between the myotonic dystrophy locus and a new polymorphic DNA marker. Am J Hum Genet (1991) 1.64
Paternal origin of new mutations in von Recklinghausen neurofibromatosis. Nature (1990) 1.64
Evidence from family studies that the gene causing Huntington disease is telomeric to D4S95 and D4S90. Am J Hum Genet (1989) 1.64
Recombination hotspot in NF1 microdeletion patients. Hum Mol Genet (2001) 1.61
Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin. Hum Mol Genet (1999) 1.59
A genetic register for Huntington's chorea in South Wales. J Med Genet (1982) 1.56
Localization of a human Na+,K+-ATPase alpha subunit gene to chromosome 19q12----q13.2 and linkage to the myotonic dystrophy locus. Genomics (1988) 1.55
Absence of genetic heterogeneity in Duchenne muscular dystrophy shown by a linkage study using two cloned DNA sequences. J Med Genet (1983) 1.54
Becker muscular dystrophy: correlation of deletion type with clinical severity. J Med Genet (1990) 1.50
Dentatorubral and pallidoluysian atrophy (DRPLA). Clinical and neuropathological findings in genetically confirmed North American and European pedigrees. Mov Disord (1997) 1.49
Mild form of Hunter's syndrome: clinical delineation based on 31 cases. Arch Dis Child (1982) 1.46
Age of onset in Huntington disease: sex specific influence of apolipoprotein E genotype and normal CAG repeat length. J Med Genet (1999) 1.45
Congenital dystrophia myotonica. Neurology (1973) 1.45
Multiple coronary artery aneurysms in a child with neurofibromatosis type 1. Eur J Pediatr (2000) 1.44
Regional mapping of facioscapulohumeral muscular dystrophy gene on 4q35: combined analysis of an international consortium. Am J Hum Genet (1992) 1.44
Genetic testing for familial hypertrophic cardiomyopathy in newborn infants. BMJ (1995) 1.44
Carrier detection in Duchenne muscular dystrophy. Evidence from a study of obligatory carriers and mothers of isolated cases. Arch Dis Child (1979) 1.43
Genetic counselling in facioscapulohumeral muscular dystrophy. J Med Genet (1991) 1.42
Sanfilippo A disease in the fetus. J Med Genet (1974) 1.40
Marfan syndrome: exclusion of genetic linkage to the COL1A2 gene. Clin Genet (1986) 1.40
Estimation of age dependent penetrance in facioscapulohumeral muscular dystrophy by minimising ascertainment bias. J Med Genet (1989) 1.39
Selection for presymptomatic testing for Huntington's disease: who decides? J Med Genet (1996) 1.39
Recurrence risk in osteogenesis imperfecta congenita. Lancet (1980) 1.38
A genetic marker for Huntington's chorea. Br Med J (Clin Res Ed) (1983) 1.38
Genetic prediction and family structure in Huntington's chorea. Br Med J (Clin Res Ed) (1985) 1.38
Genetic linkage relationships of seven DNA probes with Duchenne and Becker muscular dystrophy. Hum Genet (1985) 1.33
SPRED1 mutations (Legius syndrome): another clinically useful genotype for dissecting the neurofibromatosis type 1 phenotype. J Med Genet (2009) 1.32
The apolipoprotein CII gene: subchromosomal localisation and linkage to the myotonic dystrophy locus. Hum Genet (1985) 1.31
X-linked hypohidrotic ectodermal dysplasia: DNA probe linkage analysis and gene localization. Hum Genet (1987) 1.31
Early diagnosis and secondary prevention of Duchenne muscular dystrophy. Arch Dis Child (1989) 1.30
Mapping genetic markers on human chromosome 19 using subchromosomal fragments in somatic cell hybrids. Cytogenet Cell Genet (1986) 1.29
Cerebellar haemangioblastoma and von Hippel-Lindau disease. Brain (1986) 1.29
Linkage analysis of peripheral neurofibromatosis (Von Recklinghausen disease) and chromosome 19 markers linked to myotonic dystrophy. J Med Genet (1986) 1.26
Genetic linkage between Huntington's disease and the DNA polymorphism G8 in South Wales families. J Med Genet (1985) 1.25
Mental retardation and cardiovascular malformations in NF1 microdeleted patients point to candidate genes in 17q11.2. J Med Genet (2004) 1.25
Duchenne muscular dystrophy in Wales: a 15 year study, 1971 to 1986. J Med Genet (1989) 1.24
Implications of diagnostic delay in Duchenne muscular dystrophy. Br Med J (Clin Res Ed) (1983) 1.23
Huntington's disease predictive testing: the case for an assessment approach to requests from adolescents. J Med Genet (1996) 1.23
Hereditary distal spinal muscular atrophy with vocal cord paralysis. J Neurol Neurosurg Psychiatry (1980) 1.23
Neurofibromatous neuropathy in neurofibromatosis 1 (NF1). J Med Genet (2004) 1.23
The natural history of congenital myotonic dystrophy: mortality and long term clinical aspects. Arch Dis Child (1993) 1.22
X-linked hypohidrotic ectodermal dysplasia: localization within the region Xq11-21.1 by linkage analysis and implications for carrier detection and prenatal diagnosis. Am J Hum Genet (1988) 1.21
Localisation of genetic markers and orientation of the linkage group on chromosome 19. Hum Genet (1984) 1.21
Anal abnormalities in childhood myotonic dystrophy--a possible source of confusion in child sexual abuse. Arch Dis Child (1992) 1.21
Attitudes of parents of cystic fibrosis children towards neonatal screening and antenatal diagnosis. Clin Genet (1990) 1.20
D4F104S1 deletion in facioscapulohumeral muscular dystrophy: phenotype, size, and detection. Neurology (2003) 1.20
The use of flanking markers in prediction for Duchenne muscular dystrophy. Arch Dis Child (1986) 1.19
The natural history of the severe form of Hunter's syndrome: a study based on 52 cases. Dev Med Child Neurol (1983) 1.19
Cerebral malaria. Br Med J (1968) 1.18
Mendelian inheritance or transmissible agent? The lesson Kuru and the Australia antigen. J Med Genet (1977) 1.18
Mannosidosis in two brothers: prolonged survival in the severe phenotype. Clin Genet (1982) 1.16
Exclusion of COL2A1 as a candidate gene in a family with Wagner-Stickler syndrome. J Med Genet (1990) 1.16
Paternal origin of the chromosomal deletion resulting in Wolf-Hirschhorn syndrome. J Med Genet (1991) 1.15